Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1541-1550

  Moriya, Shota ^a   Che, Xiao Fang ^a   Komatsu, Seiichiro ^a   Abe, Akihisa ^a   Kawaguchi, Tomohiro ^a   Gotoh, Akihiko ^a   Inazu, Masato ^a   Tomoda, Akio ^a   Miyazawa, Keisuke ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Autophagy; Bortezomib; CHOP; Clarithromycin; ER stress; Macrolide antibiotics; Myeloma

Indexed keywords

AZITHROMYCIN; BIM PROTEIN; BORTEZOMIB; CASPASE 3; CLARITHROMYCIN; CONCANAMYCIN A; DR5 PROTEIN; ERYTHROMYCIN; GADD34 PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; MACROLIDE; PROTEIN BAX; TRANSCRIPTION FACTOR; TRB3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION; IN VITRO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; UPREGULATION;

ANIMALS; APOPTOSIS; AUTOPHAGY; AZITHROMYCIN; BORONIC ACIDS; CELL LINE, TUMOR; CLARITHROMYCIN; ENDOPLASMIC RETICULUM STRESS; ERYTHROMYCIN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROLIDES; MICE; MULTIPLE MYELOMA; PYRAZINES; TRANSCRIPTION FACTOR CHOP;

EID: 84875985028     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1870     Document Type: Article

References (54)

1. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
2. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A and Harousseau JL: Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120: 947-959, 2012.
3. Anderson KC: New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program 2011: 184-190, 2011.
4. Bird JM, Owen RG, D'Sa S, et al: Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154: 32-75, 2011.
5. Laubach J, Richardson P and Anderson K: Multiple myeloma. Annu Rev Med 62: 249-264, 2011.
6. Feinman R, Siegel DS and Berenson J: Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin Adv Hematol Oncol 2: 162-166, 2004.
7. Li ZW, Chen H, Campbell RA, Bonavida B and Berenson JR: NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15: 391-399, 2008.
8. Hideshima T, Chauhan D, Richardson P, et al: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277: 16639-16647, 2002. (Pubitemid 34967682)
9. Chauhan D, Hideshima T, Mitsiades C, Richardson P and Anderson KC: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4: 686-692, 2005. (Pubitemid 40601851)
10. Kawaguchi T, Miyazawa K, Moriya S, et al: Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. Int J Oncol 38: 643-654, 2011.
11. Hideshima T, Ikeda H, Chauhan D, et al: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114: 1046-1052, 2009.
12. Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR and Sun SY: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J Biol Chem 285: 16096-16104, 2010.
13. Jia L, Gopinathan G, Sukumar JT and Gribben JG: Blocking autophagy prevents bortezomib-induced NF-kappaB activation by reducing I-kappaBalpha degradation in lymphoma cells. PLoS One 7: e32584, 2012.
14. Conticello C, Giuffrida R, Adamo L, et al: NF-kappaB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res 35: 52-60, 2011.
15. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP and Boise LH: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916, 2006. (Pubitemid 43882644)
16. Meister S, Schubert U, Neubert K, et al: Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792, 2007. (Pubitemid 46383406)
17. Periyasamy Thandavan S, Jackson WH, Samaddar JS, et al: Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy 6: 19-35, 2010.
18. Fels DR, Ye J, Segan AT, et al: Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68: 9323-9330, 2008.
19. Ri M, Iida S, Nakashima T, et al: Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512, 2010.
20. Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007. (Pubitemid 46985379)
21. Herr I and Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 98: 2603-2614, 2001.
22. Verfaillie T, Salazar M, Velasco G and Agostinis P: Linking ER stress to autophagy: potential implications for cancer therapy. Int J Cell Biol 2010: 930509, 2010.
23. Mizushima N and Levine B: Autophagy in mammalian development and differentiation. Nat Cell Biol 12: 823-830, 2010.
24. Janku F, McConkey DJ, Hong DS and Kurzrock R: Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8: 528-539, 2011.
25. Kirkin V, McEwan DG, Novak I and Dikic I: A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269, 2009.
26. Korolchuk VI, Menzies FM and Rubinsztein DC: Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584: 1393-1398, 2010.
27. Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy 3: 542-545, 2007. (Pubitemid 350060049)
28. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H and Hata H: Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 37: 815-820, 2010.
29. Renna M, Schaffner C, Brown K, et al: Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 121: 3554-3563, 2011.
30. Moriya S, Miyazawa K, Kawaguchi T, Che XF and Tomoda A: Involvement of endoplasmic reticulum stress-mediated CHOP (GADD153) induction in the cytotoxicity of 2-aminophenoxazine-3-one in cancer cells. Int J Oncol 39: 981-988, 2011.
31. Shen D, Coleman J, Chan E, Nicholson TP, Dai L, Sheppard PW and Patton WF: Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies. Cell Biochem Biophys 60: 173-185, 2011.
32. Klionsky DJ, Abdalla FC, Abeliovich H, et al: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544, 2012.
33. Komatsu S, Miyazawa K, Moriya S, et al: Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells. Int J Oncol 40: 1029-1039, 2012.
34. Nawrocki ST, Carew JS, Maclean KH, et al: Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 112: 2917-2926, 2008.
35. Tabas I and Ron D: Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190, 2011.
36. Bays NW, Gardner RG, Seelig LP, Joazeiro CA and Hampton RY: Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat Cell Biol 3: 24-29, 2001. (Pubitemid 32114828)
37. Tsai YC and Weissman AM: Ubiquitylation in ERAD: reversing to go forward? PLoS Biol 9: e1001038, 2011.
38. Lee JY, Koga H, Kawaguchi Y, et al: HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J 29: 969-980, 2010.
39. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL and Anderson KC: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102: 8567-8572, 2005. (Pubitemid 40862776)
40. Rodriguez Gonzalez A, Lin T, Ikeda AK, Simms Waldrip T, Fu C and Sakamoto KM: Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 68: 2557-2560, 2008. (Pubitemid 351556250)
41. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D and Harris AL: The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 69: 4415-4423, 2009.
42. Rzymski T, Milani M, Singleton DC and Harris AL: Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8: 3838-3847, 2009.
43. Rzymski T, Milani M, Pike L, et al: Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29: 4424-4435, 2010.
44. Schafranek L, Leclercq TM, White DL and Hughes TP: Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leuk Lymphoma 54: 198-201, 2013.
45. Carella AM, Beltrami G, Pica G, Carella A and Catania G: Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 53: 1409-1411, 2012.
46. Gay F, Rajkumar SV, Coleman M, et al: Clarithromycin (Biaxin)- lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 85: 664-669, 2010.
47. Niesvizky R, Jayabalan DS, Christos PJ, et al: BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111: 1101-1109, 2008. (Pubitemid 351213388)
48. Mikasa K, Sawaki M, Kita E, et al: Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy 43: 288-296, 1997. (Pubitemid 27230874)
49. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H and Hibi T: Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 24: 3723-3730, 2004. (Pubitemid 40476069)
50. Wada T, Sata M, Sato J, et al: Clarithromycin suppresses invasiveness of human lung adenocarcinoma cells. Chemotherapy 53: 77-84, 2007. (Pubitemid 46377214)
51. Yatsunami J, Fukuno Y, Nagata M, et al: Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett 147: 17-24, 1999.
52. Hamada K, Kita E, Sawaki M, Mikasa K and Narita N: Antitumor effect of erythromycin in mice. Chemotherapy 41: 59-69, 1995. (Pubitemid 24375194)
53. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R and Tashiro Y: Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 23: 33-42, 1998. (Pubitemid 28223394)
54. Klionsky DJ, Elazar Z, Seglen PO and Rubinsztein DC: Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy 4: 849-950, 2008.